Citadel Advisors’s VanEck Pharmaceutical ETF PPH Stock Holding History

Citadel Advisors’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,600	Closed	-$578K	–	13956
2025 Q4	$578K	Sell	5,600 -2,700	-33%	-$263K	﹤0.01%	8681
2025 Q3	$750K	Sell	8,300 -4,700	-36%	-$412K	﹤0.01%	8179
2025 Q2	$1.14M	Sell	13,000 -45,800	-78%	-$3.97M	﹤0.01%	6785
2025 Q1	$5.36M	Buy	58,800 +32,300	+122%	+$2.91M	﹤0.01%	3751
2024 Q4	$2.29M	Buy	26,500 +25,500	+2,550%	+$2.31M	﹤0.01%	5349
2024 Q3	$95K	Sell	1,000 -200	-17%	-$19K	﹤0.01%	11185
2024 Q2	$110K	Sell	1,200 -1,100	-48%	-$98.2K	﹤0.01%	10781
2024 Q1	$209K	Sell	2,300 -11,000	-83%	-$963K	﹤0.01%	10240
2023 Q4	$1.08M	Buy	13,300 +11,900	+850%	+$933K	﹤0.01%	6510
2023 Q3	$112K	Buy	1,400 +1,000	+250%	+$80.6K	﹤0.01%	10751
2023 Q2	$31.5K	Sell	400 -2,000	-83%	-$157K	﹤0.01%	12298
2023 Q1	$186K	Sell	2,400 -300	-11%	-$23.1K	﹤0.01%	10304
2022 Q4	$210K	Buy	+2,700	New	+$199K	﹤0.01%	10039
2022 Q3	–	Sell	-4,300	Closed	-$330K	–	13372
2022 Q2	$330K	Hold	4,300	–	–	﹤0.01%	9594
2022 Q1	$343K	Buy	4,300 +400	+10%	+$30.6K	﹤0.01%	10288
2021 Q4	$300K	Sell	3,900 -1,000	-20%	-$74.4K	﹤0.01%	10924
2021 Q3	$356K	Buy	4,900 +1,400	+40%	+$104K	﹤0.01%	10684
2021 Q2	$256K	Buy	+3,500	New	+$250K	﹤0.01%	11649
2020 Q3	–	Sell	-8,000	Closed	-$498K	–	10596
2020 Q2	$498K	Sell	8,000 -200	-2%	-$12.1K	﹤0.01%	7084
2020 Q1	$446K	Sell	8,200 -300	-4%	-$18.5K	﹤0.01%	6648
2019 Q4	$546K	Buy	+8,500	New	+$512K	﹤0.01%	6671
2016 Q4	–	Sell	-4,200	Closed	-$241K	–	7707
2016 Q3	$241K	Buy	+4,200	New	+$252K	﹤0.01%	6033

Other funds holding PPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JSAM

J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return

AWC

Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return

Citadel Advisors's PPH Position: Q2 2026 in Review

Citadel Advisors reduced its VanEck Pharmaceutical ETF (PPH) stake by 51% in Q2 2026, selling an estimated $3.51M and leaving 33,171 shares worth $3.63M. The position accounts for ﹤0.01% of the portfolio, ranked #5305.

Citadel Advisors first reported a position in PPH in Q1 2014 and has held it in 47 quarters since. The position peaked at $6.97M in Q1 2026. 147 funds tracked by Wall St. Rank hold PPH as of Q2 2026.

Citadel Advisors held 33,171 shares of VanEck Pharmaceutical ETF worth $3.63M as of Q2 2026.
Citadel Advisors sold 33,915 VanEck Pharmaceutical ETF shares in Q2 2026, an estimated $3.51M.
VanEck Pharmaceutical ETF made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #5305 holding.
Citadel Advisors first reported a position in VanEck Pharmaceutical ETF in Q1 2014 and has held it in 47 quarters since.
Citadel Advisors's VanEck Pharmaceutical ETF position peaked at $6.97M in Q1 2026.
147 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.